![]() |
市場調查報告書
商品編碼
1479991
全球外泌體研究市場評估:依產品和服務、依適應症類型、依應用類型、依最終用戶、依地區、機會、預測(2017-2031)Exosome Research Market Assessment, By Product and Service, By Indication Type, By Application Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球外泌體研究市場規模預計將從 2023 年的 2.0344 億美元增至 2031 年的 7.3264 億美元,預計 2024-2031 年的複合年增長率為 17.37%。 近年來市場呈現顯著成長,預計未來將維持穩定擴張速度。
外泌體是細胞釋放的微小細胞外囊泡,在細胞間通訊中扮演重要角色。 這些囊泡由蛋白質、脂質和核酸等多種生物分子組成,可用於診斷和治療目的。 該市場包括多種產品,例如用於分析、純化和分離外泌體的檢測試劑盒、分離試劑盒和表徵試劑盒。 這些外泌體可用作疾病診斷和監測以及靶向治療中藥物遞送的生物標記。
由於研發支出增加、慢性病盛行率上升、老年人口增加以及整個醫療保健領域的技術擴展,全球外泌體研究市場預計將快速成長。 醫療保健提供者和行業領導者正在合作,為患者提供最佳的診斷方法。 政府機構和私人公司已籌集資金並進行大量投資。 當這些巨頭公司推出或開發新產品時,併購、投資和合作等策略性舉措就會出現。 2022 年 8 月,Creative Biolabs 宣佈推出一個名為 Nanosight 平台的先進平台,用於外泌體表徵。 本平台可供任何研究機構或產業客戶用於尺寸分佈分析、外泌體濃度測量、表型評估等。
研發費用增加
由於研究投資的增加,全球外泌體研究市場正在顯著成長。 有了這樣的資金,科學家現在能夠更詳細、更深入地研究外泌體,從而提高知識和治療應用。 透過增加外泌體研究的資金,可以開發用於外泌體分離、分析和表徵的新技術和方法。 因此,外泌體研究市場正在見證新產品和服務的開發,以及外泌體在各種疾病診斷和治療中的新用途。 更廣泛的研究重點和外泌體臨床應用知識的提高推動了外泌體研究市場的成長。 近年來,以外泌體為基礎的療法已被納入多家公司的研發管線中。 外泌體研究市場的主要關注領域之一是開發新型外泌體分離和豐富化技術。 使用微流體裝置進行高通量外泌體萃取以及開發從特定細胞類型中分離外泌體的新技術是該領域最新發展的例子。
例如,精準腫瘤學專家 Guardant Health 在 2022 年開發了一項名為 Guardant360 測試的測試。 該測試使用從血液中的外泌體中提取的循環腫瘤 DNA (ctDNA) 來檢測與癌症相關的突變。 這種液體活檢測試是傳統組織活檢的一種非侵入性替代方法,只需抽血即可檢測和監測多種類型的癌症。
慢性病盛行率增加
全球外泌體研究市場受到慢性病盛行率上升的顯著影響。 全球數百萬人受到癌症、心臟病、神經系統疾病等慢性疾病的影響,對公共衛生帶來嚴重課題。 由於外泌體有望作為治療和診斷工具來治療各種類型的慢性疾病,因此外泌體研究市場正在擴大。 目前,由於慢性病盛行率不斷上升,研究受到越來越多的關注,這為外泌體在疾病監測、診斷和治療中發揮關鍵作用創造了機會。
本報告研究和分析了全球外泌體研究市場,提供市場規模和預測、市場動態以及主要參與者的現狀和前景。
Global exosome research market is projected to witness a CAGR of 17.37% during the forecast period 2024-2031, growing from USD 203.44 million in 2023 to USD 732.64 million in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.
Exosomes are tiny extracellular vesicles released by cells and play an important role in intercellular communication. These vesicles consist of different biomolecules such as proteins, lipids, and nucleic acids, which can be used for diagnostic and therapeutic purposes. Its market includes various products such as detection kits, isolation kits, and characterization kits used for the analysis, purification, and isolation of exosomes. These exosomes can be used as biomarkers to diagnose diseases and monitor them, as well as for drug delivery in targeted therapies.
The global exosome research market is expected to grow rapidly due to increasing expenditure on research and development, rising prevalence of chronic diseases, rising geriatric population, and expanding technology throughout the healthcare sector. Healthcare providers and industry giants are coming together to bring out their best diagnostic approaches for patients. Funds are being raised, and a hefty amount is being invested by both government bodies and private companies. Strategic initiatives such as mergers and acquisitions, investments, and partnerships come into play when these huge companies are trying to launch or develop a new product. In August 2022, Creative Biolabs launched an advanced platform called the Nanosight platform, which is used for exosome characterization. This platform is accessible to all kinds of research and industrial customers for size distribution analysis, exosome concentration measurement, and phenotypic evaluation.
Increasing Expenditure on Research and Development
The global market for exosome research has grown significantly due to increasing research investments. With the help of this funding, scientists have now been able to study exosomes in greater detail and with greater depth, which has improved their knowledge and therapeutic applications. The development of novel technologies and methods for the isolation, analysis, and characterization of exosomes has been made possible by increased funding for exosome research. As a result, the market for exosome research has seen the development of new goods and services as well as novel uses for exosomes in the diagnosis and treatment of various diseases. The exosome research market has grown because of this broader research focus, which has also improved knowledge of the clinical uses of exosomes. Exosome-based treatments have lately been included in the pipelines of several businesses. One of the main areas of concentration for the exosome research market has been the creation of novel and enhanced exosome isolation technologies. The use of microfluidic devices for high-throughput exosome extraction and the creation of novel techniques for separating exosomes from particular cell types are examples of recent developments in this field.
For instance, Guardant Health, which specializes in precision oncology, developed a test called the Guardant360 test in 2022 that utilizes circulating tumor DNA (ctDNA), which is extracted from exosomes in the bloodstream and used to detect cancer-related mutations. This liquid biopsy test offers a non-invasive alternative to traditional tissue biopsies, allowing for the detection and monitoring of various cancer types through a simple blood draw.
Increasing Prevalence of Chronic Diseases
The global market for exosome research is being significantly impacted by the rising incidence of chronic illnesses. Millions of individuals worldwide are impacted by chronic diseases like cancer, heart disease, and neurological problems, which pose serious challenges to public health. The exosome research market is expanding as a result of exosomes' potential as therapeutic and diagnostic tools to treat different types of chronic diseases. Research is now receiving more attention due to the rise in prevalence of chronic illnesses, which presents a chance for exosomes to play a crucial role in disease monitoring, diagnosis, and therapy.
The industry is expanding because researchers are looking at exosomes' potential as medicines and biomarkers. Exosomes have shown promising results as a unique class of treatments that can transport medications and genetic material to certain cells and tissues. Exosome-based therapies and products have been developed in response to the growing need for innovative treatments brought on by the increased prevalence of chronic diseases.
Exosomes found in biological fluids can be analyzed to find biomarkers that might point to the existence of a disease. This has fueled the development of fresh exosome-based diagnostic instruments and assays, which has increased demand for exosome research. There is a huge market demand for innovative and efficient treatments as well as diagnostic instruments due to the rising incidence of chronic illnesses.
Exosome research has increased in response to demand, as exosomes have shown promise as a potential remedy for various ailments. A report published by NIH in January 2023 stated that in the US, the number of people who are above the age of 50 will increase from 137.25 million in 2020 to 221.13 million in 2050, a significant increase of 61.11%. The number of people 50 years of age and older who have at least one chronic illness is predicted to increase from 71.522 million in 2020 to 142.66 million in 2050.
Growth In Various Therapeutic Applications of Exosomes
Exosomes may be employed as a platform for therapeutic intervention for various diseases. Exosomes can be used in clinical settings as cell-free substitutes to treat a variety of illnesses and promote tissue regeneration since they can carry therapeutic cargo components without causing cellular toxicity or immunological rejection. Exosomes produced from stem cells have the benefit of using the regenerative and anti-inflammatory properties of their parent cells; as a result, respiratory virus infections can be treated with exosomal therapy. Given their natural material transportation qualities, capacity to sustain intrinsic long-term circulation, and high biocompatibility - all of which make them ideal for the delivery of a wide range of proteins, chemicals, and nucleic acids - exosomes make great drug delivery vehicles.
Exosomes have proved to be promising as intercellular communication mediators, potentially transporting functional proteins, mRNA transcripts, and miRNAs to cells all over the body, according to a few research investigations. Exosomes are biocompatible and are effective agents in a variety of conditions, including organ injuries and ailments of the heart, kidney, liver, and lungs. They are derived from specific cell types, such as mesenchymal and dendritic stem cells. Even though research on exosome uses has advanced at a fast pace, there are still several obstacles in the way of creating treatments based on exosomes, especially when it comes to producing exosome formulations because of their poor productivity and heterogeneity. But finding a way to combat this and be able to fully use their potential in a variety of ways is promising for the expansion of the exosome research market.
In April 2024, Exo Biologics, a clinical-stage biotech company, announced that it has successfully secured a total of EUR 16 million in Series A funding for the development of exosome-based therapies. These funds will be used by them to support its future and ongoing trials. It will also continue its manufacturing expansion, including upgrading its unique production platform, ExoPulse (TM), and expanding partnerships to enable pan-market access to the platform and GMP clinical grade exosomes for faster access to clinical trials.
North America Dominates the Exosome Research Market
North America accounts for the highest market shares of exosomes due to its advanced healthcare system, favorable laws, an extensive network of multinational corporations, and high level of knowledge among people about healthcare and diagnostics. Numerous government-funded studies have been carried out in the region to investigate the potential involvement of medications utilizing exosomes in various cancer types, including pancreatic cancer, melanoma, lung cancer, and breast cancer. Universities like Yale University and Michigan State University have partnered with and are being supported by companies like Merck and Exosome Diagnostic to carry out clinical trials in the US. Moreover, government funding for these endeavors is excellent. The United States is witnessing widespread use of cutting-edge micro-nanotechnologies for extracellular vesicles in immuno-oncology, spanning from immunomodulation to target-specific isolations. In the upcoming years, the market under study is anticipated to increase rapidly due to the implementation of new technologies.
Future Market Scenario (2024-2031F)
The market growth of exosome research is steadily increasing due to several factors. This market is expected to consistently grow in the future because of how promising its uses can be in developing diagnostics and therapeutics. As the geriatric population increases, so will the number of patients. People are widely accepting new diagnostic methods and developments to combat their illnesses. For example, according to the Lab Chip Journal, in July 2022, the United States experienced a wide adoption of emerging micro-nanotechnologies for extracellular vesicles in immuno-oncology, ranging from target-specific isolations to immunomodulation.
Key Players Landscape and Outlook
Several companies such as Thermo Fisher Scientific, Inc, Qiagen, Lonza Group Ltd, System Biosciences, LLC, Bio-Techne Corporation, Danaher Corporation, Amsbio Holdings Limited, RoosterBio, Inc., Miltenyi Biotec India Private Limited, Norgen Biotek Corp., etc. are expanding their businesses by planning and adopting new strategies. They are adopting new strategic initiatives regarding exosome research to help researchers and increase their presence in the market. New product launches, agreements based on contracts, acquisitions and mergers, investments, and partnerships are a few ways through which they are trying to achieve the same.
In July 2022, Cells for Cells, a clinical-stage biotech pioneering allogeneic stem cell and stem-cell-derived therapeutics for high-impact chronic diseases, announced a 6-month follow-up of the groundbreaking clinical data from the first-ever patient dosed with an exosome-produced therapy for osteoarthritis.
In April 2022, Global Stem Cells Group (GSCG) announced the launch of its new product with new lyophilized exosome technology. Global Stem Cells Group's new product line includes innovative anti-aging products that can regenerate cells and tissues in the body.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.